Stacy Lindborg

Stacy Lindborg serves as President & Chief Executive Officer, Board Director at IMUNON. IMUNON operates in the biotechnology sector with approximately 24.0 employees. IMUNON generates annual revenue of 125000.0.

Industry & Role Insights

• • MessageCEO tracks 381 executives in the biotechnology sector.
• • Our database includes 201,469 c suite-level executives.

Outlook Microsoft Office 365 Google Cloud Hosting Nginx WordPress.org Mobile Friendly Google Font API reCAPTCHA Remote AI

biotechnology: pharmaceutical preparations health care immunotherapy dna vaccines cancer treatment clinical trials biotech innovation immune system anti-cancer therapy nucleic acid technology therapeutics development ovarian cancer placcine platform theraplas platform fixplas platform indiplas platform personalized medicine vaccine research nucleic acid vaccines infection prevention vaccine development immunogenicity biopharmaceutical microenvironment targeting molecular biology immunology research patient centric therapeutic pipelines cancer immunotherapy clinical development biotech partnerships oncology nucleic acid therapies humoral immune response t-cell response universal cancer vaccines therapeutic innovation healthcare solutions safety & efficacy therapies for diseases biotech leadership regulatory affairs antibody production cell therapy vaccine strategy investor relations scientific presentations financial events clinical r&d vaccine technology therapeutic benefits life sciences research health wellness & fitness hospital & health care

CB

Chip Baird Chief Executive Officer at 2seventy bio at 2seventy bio

JL

Jason Loveridge CEO at 4SC AG

MM

Marie Moores Chief Operating Officer at AB Cavalli Coach & Consultant

JR

Julie Rubinstein President and Chief Operating Officer at Adaptive Biotechnologies Corp.

CH

Chris Harano President and CEO at Advanced BioCatalytics

Outreach Guidance — biotechnology Sector

Technology executives make decisions on infrastructure, tooling, and partnerships. When reaching out to Stacy Lindborg, lead with your value proposition relative to the stack they currently use. Generic pitches perform poorly; specific technical relevance is key.

Stacy Lindborg's Position in the MessageCEO Database

• •Stacy Lindborg is 1 of 1 verified executive contact we track at IMUNON.
• •365 verified executive contacts in biotechnology are in the MessageCEO database.
• •8 verified contacts work at biotechnology companies in the 24.0 employee range (same size as IMUNON).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Stacy Lindborg directly?

Stacy Lindborg's verified email address is available to MessageCEO Pro subscribers. They currently serve as President & Chief Executive Officer, Board Director at IMUNON. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Stacy Lindborg work for?

Stacy Lindborg is President & Chief Executive Officer, Board Director at IMUNON, a company in the biotechnology sector with 24.0 employees.

Can I pitch or sell to Stacy Lindborg?

As President & Chief Executive Officer, Board Director at IMUNON, Stacy Lindborg is a key decision-maker in the biotechnology sector. MessageCEO Pro gives you verified email to reach Stacy Lindborg directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Stacy Lindborg in?

Stacy Lindborg works in the biotechnology industry as President & Chief Executive Officer, Board Director at IMUNON. MessageCEO provides verified contact information for executives across all major industries.

Is Stacy Lindborg's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Stacy Lindborg's profile is kept up-to-date with the latest available information.

Last updated: July 23, 2026